These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 12244784

  • 1. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J, Tovar I, Martínez P.
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract] [Full Text] [Related]

  • 2. [Merger of bone biology and immunology].
    Suda T, Shima N, Higashio K.
    Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
    [No Abstract] [Full Text] [Related]

  • 3. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS.
    J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P.
    Circ Res; 2004 Nov 26; 95(11):1046-57. PubMed ID: 15564564
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
    Hofbauer LC, Heufelder AE, Erben RG.
    J Rheumatol; 2001 Apr 26; 28(4):685-7. PubMed ID: 11327234
    [No Abstract] [Full Text] [Related]

  • 11. Osteoclast precursors, RANKL/RANK, and immunology.
    Xing L, Schwarz EM, Boyce BF.
    Immunol Rev; 2005 Dec 26; 208():19-29. PubMed ID: 16313338
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rheumatic diseases: the effects of inflammation on bone.
    Walsh NC, Crotti TN, Goldring SR, Gravallese EM.
    Immunol Rev; 2005 Dec 26; 208():228-51. PubMed ID: 16313352
    [Abstract] [Full Text] [Related]

  • 14. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP, Schwarz EM.
    J Cell Biochem; 2006 Feb 01; 97(2):226-32. PubMed ID: 16240334
    [Abstract] [Full Text] [Related]

  • 15. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
    Liu XH, Kirschenbaum A, Yao S, Levine AC.
    Ann N Y Acad Sci; 2006 Apr 01; 1068():225-33. PubMed ID: 16831922
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.
    Hofbauer LC.
    Eur J Endocrinol; 1999 Sep 01; 141(3):195-210. PubMed ID: 10474114
    [No Abstract] [Full Text] [Related]

  • 18. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases.
    Siggelkow H, Eidner T, Lehmann G, Viereck V, Raddatz D, Munzel U, Hein G, Hüfner M.
    J Bone Miner Res; 2003 Mar 01; 18(3):529-38. PubMed ID: 12619938
    [Abstract] [Full Text] [Related]

  • 19. Bone cancer pain and the role of RANKL/OPG.
    Clohisy DR, Mantyh PW.
    J Musculoskelet Neuronal Interact; 2004 Sep 01; 4(3):293-300. PubMed ID: 15615497
    [Abstract] [Full Text] [Related]

  • 20. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI.
    Curr Opin Pharmacol; 2004 Aug 01; 4(4):340-6. PubMed ID: 15251126
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.